Genital Herpes - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 107
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GE1FCDDDF3AEN
Leaflet:

Download PDF Leaflet

Genital Herpes - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Genital Herpes - Pipeline Review, H2 2016’, provides an overview of the Genital Herpes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Genital Herpes
  • The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects
  • The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Genital Herpes
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genital Herpes
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Genital Herpes Overview
Therapeutics Development
Pipeline Products for Genital Herpes - Overview
Pipeline Products for Genital Herpes - Comparative Analysis
Genital Herpes - Therapeutics under Development by Companies
Genital Herpes - Therapeutics under Investigation by Universities/Institutes
Genital Herpes - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Genital Herpes - Products under Development by Companies
Genital Herpes - Products under Investigation by Universities/Institutes
Genital Herpes - Companies Involved in Therapeutics Development
Admedus Ltd
Agenus, Inc.
AiCuris GmbH & Co. KG
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
GenVec, Inc.
Immune Design Corp.
JN-International Medical Corporation
Mymetics Corporation
NanoBio Corporation
NanoViricides, Inc.
PaxVax, Inc.
Profectus BioSciences, Inc.
Redbiotec AG
Sanofi Pasteur SA
Shulov Innovative Science Ltd.
Starpharma Holdings Limited
Tomegavax, Inc.
Vaccibody AS
Vaxart, Inc.
Vical Incorporated
Genital Herpes - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acyclovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEN-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genital herpes (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GV-2207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus [type 1, 2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus [type 1, 2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSV-529 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pritelivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Genital Herpes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCLHB-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCLHM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Genital Herpes - Dormant Projects
Genital Herpes - Discontinued Products
Genital Herpes - Product Development Milestones
Featured News & Press Releases
Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits
Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing
Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging
Feb 03, 2016: Model helps decide drug dose for clinical testing
Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003
Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003
Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine
Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015
May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003
Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences
Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes
Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection
Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation
Nov 07, 2013: Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Genital Herpes, H2 2016
Number of Products under Development for Genital Herpes - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Genital Herpes - Pipeline by Admedus Ltd, H2 2016
Genital Herpes - Pipeline by Agenus, Inc., H2 2016
Genital Herpes - Pipeline by AiCuris GmbH & Co. KG, H2 2016
Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
Genital Herpes - Pipeline by Genocea Biosciences, Inc., H2 2016
Genital Herpes - Pipeline by GenVec, Inc., H2 2016
Genital Herpes - Pipeline by Immune Design Corp., H2 2016
Genital Herpes - Pipeline by JN-International Medical Corporation, H2 2016
Genital Herpes - Pipeline by Mymetics Corporation, H2 2016
Genital Herpes - Pipeline by NanoBio Corporation, H2 2016
Genital Herpes - Pipeline by NanoViricides, Inc., H2 2016
Genital Herpes - Pipeline by PaxVax, Inc., H2 2016
Genital Herpes - Pipeline by Profectus BioSciences, Inc., H2 2016
Genital Herpes - Pipeline by Redbiotec AG, H2 2016
Genital Herpes - Pipeline by Sanofi Pasteur SA, H2 2016
Genital Herpes - Pipeline by Shulov Innovative Science Ltd., H2 2016
Genital Herpes - Pipeline by Starpharma Holdings Limited, H2 2016
Genital Herpes - Pipeline by Tomegavax, Inc., H2 2016
Genital Herpes - Pipeline by Vaccibody AS, H2 2016
Genital Herpes - Pipeline by Vaxart, Inc., H2 2016
Genital Herpes - Pipeline by Vical Incorporated, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Genital Herpes - Dormant Projects, H2 2016
Genital Herpes - Dormant Projects (Contd.1), H2 2016
Genital Herpes - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Genital Herpes, H2 2016
Number of Products under Development for Genital Herpes - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Admedus Ltd
Agenus, Inc.
AiCuris GmbH & Co. KG
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
GenVec, Inc.
Immune Design Corp.
JN-International Medical Corporation
Mymetics Corporation
NanoBio Corporation
NanoViricides, Inc.
PaxVax, Inc.
Profectus BioSciences, Inc.
Redbiotec AG
Sanofi Pasteur SA
Shulov Innovative Science Ltd.
Starpharma Holdings Limited
Tomegavax, Inc.
Vaccibody AS
Vaxart, Inc.
Vical Incorporated
Skip to top


Genital Herpes - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Genital Herpes - API Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
NanoViricides, Inc. - Product Pipeline Review - 2016 US$ 1,500.00 Aug, 2016 · 46 pages
Seek - Product Pipeline Review - 2014 US$ 1,125.00 Oct, 2014 · 42 pages

Ask Your Question

Genital Herpes - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: